Does YouTube provide high quality information? Assessment of secukinumab videos
- 97 Downloads
The Internet is a widely used source for obtaining health-related information. With the widespread use of the Internet, access to information has become easier. YouTube is one of the major sources for health-related videos globally. YouTube provides a wide range of health-related information, but there are doubts about its quality and reliability. Therefore, we aimed to assess the quality of the most viewed secukinumab videos on YouTube. This is a descriptive study. A total of 180 secukinumab videos returned by the YouTube search engine (http://www.youtube.com) in response to a keywords query were evaluated in the study. The Global Quality Scale (GQS) was used to assess educational quality, and three groups were created: high quality, intermediate quality, and low quality. Video parameters were compared among the quality groups. After applying the exclusion criteria, 53 videos were analyzed; 18 (34%) videos were in the high-quality group, 17 (32%) were in the intermediate-quality group, and 18 (34%) were in the low-quality group. No significant difference was detected in terms of the number of views, likes, dislikes, and comments per day between the groups (p > 0.05). YouTube has a mixed structure of high, intermediate, and low-quality videos. The number of views, likes, dislikes, and comments per day should not be accepted as an indicator of quality for YouTube videos. In addition, patients should consider the importance of sources when obtaining online health-related information.
KeywordsYouTube Secukinumab Ankylosing spondylitis Psoriatic arthritis
We thank Tuba Tulay Koca for the video reviews.
BFK and MSA designed the study; BFK and MSA reviewed the videos and provided the data; BFK analyzed the data; MSA contributed the analysis tools; BFK and MSA authored and reviewed drafts of the paper; BFK prepared the tables; BFK and MSA made the revisions; BFK and MSA approved the final manuscript as submitted and agree to be accountable for all aspects of the work.
Compliance with ethical standards
Conflict of interest
The authors declare no conflicts of interest.
We did not evaluate any human participants or animals in this study. Videos that anyone can access were evaluated. Therefore, there was no need for approval of the ethics committee for this study.
- 1.Mease PJ, McInnes IB, Kirkham B, Kavanaugh A, Rahman P, van der Heijde D, Landewé R, Nash P, Pricop L, Yuan J, Richards HB, Mpofu S, FUTURE 1 Study Group (2015) Secukinumab inhibition of interleukin-17A in patients with psoriatic arthritis. N Engl J Med 373:1329–1339. https://doi.org/10.1056/NEJMoa1412679 CrossRefGoogle Scholar
- 2.Langley RG, Elewski BE, Lebwohl M, Reich K, Griffiths CE, Papp K, Puig L, Nakagawa H, Spelman L, Sigurgeirsson B, Rivas E, Tsai TF, Wasel N, Tyring S, Salko T, Hampele I, Notter M, Karpov A, Helou S, Papavassilis C, ERASURE Study Group; FIXTURE Study Group (2014) Secukinumab in plaque psoriasis—results of two phase 3 trials. N Engl J Med 371:326–338. https://doi.org/10.1056/NEJMoa1314258 CrossRefGoogle Scholar
- 3.Baeten D, Baraliakos X, Braun J, Sieper J, Emery P, van der Heijde D, McInnes I, van Laar JM, Landewé R, Wordsworth P, Wollenhaupt J, Kellner H, Paramarta J, Wei J, Brachat A, Bek S, Laurent D, Li Y, Wang YA, Bertolino AP, Gsteiger S, Wright AM, Hueber W (2013) Anti-interleukin-17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: a randomised, double-blind, placebo-controlled trial. Lancet 382:1705–1713. https://doi.org/10.1016/S0140-6736(13)61134-4 CrossRefGoogle Scholar